Harvey Capital Management Has Trimmed Gilead Sciences (GILD) Holding By $1.06 Million; Abercrombie & Fitch Company (ANF) Shorts Raised By 3.59%

January 17, 2018 - By Migdalia James

Harvey Capital Management Inc decreased Gilead Sciences (GILD) stake by 11.22% reported in 2017Q3 SEC filing. Harvey Capital Management Inc sold 13,050 shares as Gilead Sciences (GILD)’s stock declined 8.05%. The Harvey Capital Management Inc holds 103,210 shares with $8.36 million value, down from 116,260 last quarter. Gilead Sciences now has $106.33 billion valuation. The stock increased 1.43% or $1.15 during the last trading session, reaching $81.4. About 4.05M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since January 17, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Abercrombie & Fitch Company (NYSE:ANF) had an increase of 3.59% in short interest. ANF’s SI was 15.73M shares in January as released by FINRA. Its up 3.59% from 15.18M shares previously. With 5.93 million avg volume, 3 days are for Abercrombie & Fitch Company (NYSE:ANF)’s short sellers to cover ANF’s short positions. The SI to Abercrombie & Fitch Company’s float is 23.31%. The stock increased 0.75% or $0.14 during the last trading session, reaching $18.73. About 788,141 shares traded. Abercrombie & Fitch Co. (NYSE:ANF) has declined 47.82% since January 17, 2017 and is downtrending. It has underperformed by 64.52% the S&P500.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on February, 6. They expect $1.67 EPS, down 36.74% or $0.97 from last year’s $2.64 per share. GILD’s profit will be $2.18 billion for 12.19 P/E if the $1.67 EPS becomes a reality. After $2.23 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.11% negative EPS growth.

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.10, from 0.93 in 2017Q2. It increased, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Keybank Natl Association Oh, Ohio-based fund reported 534,835 shares. Skba Cap Limited Liability Com holds 1.89% in Gilead Sciences, Inc. (NASDAQ:GILD) or 162,150 shares. Aviva Public Limited Company holds 944,714 shares. Credit Agricole S A accumulated 2.21M shares. Lazard Asset Mngmt Lc invested 0% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Qcm Cayman Ltd, a Texas-based fund reported 4,952 shares. Baldwin Invest Management Ltd Com has invested 0.32% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Forte Cap Limited Liability Corporation Adv holds 0.86% or 33,255 shares in its portfolio. Weatherstone Capital Management holds 5,511 shares. Proshare Advsrs Ltd Liability holds 0.72% or 966,090 shares in its portfolio. Dnb Asset Mngmt As, Norway-based fund reported 134,482 shares. Barrett Asset Management Ltd Company stated it has 1,000 shares or 0.01% of all its holdings. Landscape Cap Mgmt Ltd Limited Liability Company holds 0.04% or 5,375 shares in its portfolio. Asset Mgmt Of Georgia Incorporated Ga Adv invested in 10,877 shares. Private Trust Na reported 3,758 shares stake.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences had 112 analyst reports since July 29, 2015 according to SRatingsIntel. The company was downgraded on Wednesday, February 8 by Citigroup. The rating was upgraded by Bank of America on Monday, January 18 to “Neutral”. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by Berenberg on Monday, September 12. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Market Perform” rating by Wells Fargo on Friday, December 4. Maxim Group maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Friday, February 12. Maxim Group has “Buy” rating and $115 target. The firm earned “Market Perform” rating on Thursday, October 19 by Leerink Swann. On Friday, October 6 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The firm earned “Buy” rating on Wednesday, October 28 by Maxim Group. Leerink Swann downgraded the shares of GILD in report on Tuesday, September 27 to “Mkt Perform” rating. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Hold” rating by Jefferies on Friday, October 27.

Since August 1, 2017, it had 0 buys, and 11 insider sales for $41.13 million activity. Another trade for 73,333 shares valued at $5.56 million was sold by MARTIN JOHN C. Alton Gregg H sold $1.14M worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Tuesday, August 1. Washington Robin L sold $4.40 million worth of stock or 51,820 shares. Meyers James R sold $4.99 million worth of stock or 60,000 shares.

Abercrombie & Fitch Co., through its subsidiaries, operates as a specialty retailer. The company has market cap of $1.28 billion. The Firm operates through two divisions, Abercrombie and Hollister. It currently has negative earnings. It offers knit tops, woven shirts, graphic T-shirts, fleece, sweaters, jeans, woven pants, shorts, outerwear, dresses, intimates, and swimwear; and personal care products and accessories for men, women, and kids under the Abercrombie & Fitch, abercrombie kids, Hollister, and Gilly Hicks brand names.

Among 31 analysts covering Abercrombie & Fitch Co. (NYSE:ANF), 6 have Buy rating, 10 Sell and 15 Hold. Therefore 19% are positive. Abercrombie & Fitch Co. had 110 analyst reports since August 7, 2015 according to SRatingsIntel. On Tuesday, August 30 the stock rating was maintained by Mizuho with “Neutral”. The firm has “Hold” rating by FBR Capital given on Monday, November 20. The company was downgraded on Tuesday, January 3 by Jefferies. JP Morgan maintained Abercrombie & Fitch Co. (NYSE:ANF) on Monday, March 14 with “Neutral” rating. The rating was upgraded by Evercore on Friday, November 20 to “Hold”. On Thursday, August 24 the stock rating was maintained by Robert W. Baird with “Hold”. On Wednesday, October 7 the stock rating was initiated by Citigroup with “Neutral”. FBR Capital maintained the stock with “Neutral” rating in Tuesday, August 15 report. The company was upgraded on Tuesday, August 30 by Standpoint Research. The rating was downgraded by Standpoint Research on Wednesday, May 10 to “Reduce”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: